Clinical Trials Logo

Clinical Trial Summary

HBV can be transmitted from mother-to-child, with a risk increasing according to maternal HBV DNA during pregnancy. HDV is a defective virus using HBs Ag for its own replication. Nucleosides analogues have only a minor impact on quantitative HBs Ag level. Data about vertical HDV transmission are old, justifying a new study.


Clinical Trial Description

Hepatitis B Virus (HBV) can be transmitted from mother-to-child, with a risk increasing according to maternal HBV DNA viral load during the last trimester of pregnancy. Nucleosides analogues, lamivudine, telbivudine, or nucleotides analogues, tenofovir DF decrease HBV mother-to-child transmission risk, and are recommended in Guidelines (EASL 2012) for pregnant women with HBV DNA above 1,000 000 I.U/mL. HDV is a defective virus using HBs Ag for its own replication. HDV-HBV co-infection is a re-emerging infectious disease in western countries, due to immigration of people coming from endemic areas. Nucleosides analogues have only a minor impact on quantitative HBs Ag level (Boyd A et al. AIDS Research and Human Retroviruses 2013). Data about vertical HDV transmission are old (Rizzetto, et al. J Med Virol 1982), before a large use of nucleosides/nucleotides analogues in HBV infected pregnant women, justifying a new study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02044055
Study type Observational
Source Hopital Lariboisière
Contact
Status Completed
Phase N/A
Start date October 2014
Completion date April 2017

See also
  Status Clinical Trial Phase
Completed NCT02375906 - The Hepatitis Delta International Network
Not yet recruiting NCT05394623 - Prevalence and Burden of Hepatitis D Virus Infection in China Through Preoperative Examination Test (Predict Study)
Recruiting NCT04863703 - Improvement of Portal Hypertension During Viral Suppression in Patients With Hepatitis Delta (IMPHROVE-D)
Recruiting NCT06397859 - Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis
Recruiting NCT00001971 - Evaluation of Patients With Liver Disease
Recruiting NCT06264583 - HDV-Europe: Prevalence and Outcome of HDV in HIV/HBV Coinfection
Recruiting NCT06122285 - Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy (D-SHIELD)
Recruiting NCT05928000 - HEllenic Multicenter ReAl-life CLInical Study for Bulevirtide Therapy in Chronic Hepatitis D: HERACLIS-BLV
Terminated NCT04847440 - A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection Phase 2
Recruiting NCT05936073 - DELTA DESCRIBE: the French Collaborative Project
Completed NCT00932971 - HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis Phase 2
Completed NCT06360484 - Prevalence and Clinical Characterization of Hepatitis D Virus (HDV) Infection Among Sudanese Patients With Hepatitis B Virus
Completed NCT02511431 - Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir Phase 2
Not yet recruiting NCT05451082 - Registry-based Study in Patients With Hepatitis D Virus (HDV) Infection in China
Recruiting NCT05903742 - Standardising Care for Hepatitis Delta in the Netherlands
Not yet recruiting NCT03362866 - Epidemiology of Hepatitis B, C and Delta in Reunion Island
Terminated NCT01316185 - Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV) Phase 1
Recruiting NCT05264272 - Disease Loads and Status of Treatment
Completed NCT05002907 - Epidemiology of Hepatitis B, C and D and HIV Along the Maroni River Bordering French Guiana and Suriname (MaHeVi)
Not yet recruiting NCT05467553 - A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection Phase 2